What is structure-activity relationship (SAR)?
The structure-activity relationship (SAR) describes how a molecule's chemical structure influences its biological activity, enabling researchers in drug discovery to identify key chemical groups responsible for effects, predict activities of new compounds based on structural similarities, and optimize drug development through data analysis and visualization tools like Dotmatics that facilitate efficient SAR analysis and molecular modeling.
The structure-activity relationship (SAR) is the relationship between the structure and biological activity of a molecule.
Analyzing the SAR for a given molecule allows researchers to identify the chemical group responsible for provoking a biological effect of interest. An understanding of this chemistry allows for changing the type of effect or strength of drugs by altering the chemical structure and the biological activity.
Why is the structure-activity relationship useful in drug discovery?
The structure-activity relationship is a critical concept used in the development of new compounds, especially in drug discovery.
The SAR can also be used to characterize existing molecules. Using existing data about structurally similar compounds, scientists can make predictions about the biological effects and activity of new chemical compounds.
Similar compounds typically have relatively similar physical and biological properties. SAR in drug discovery provides a useful starting point for new compound discovery and reduces the time and complexity of developing new therapeutics.
Analysis software and SAR in drug discovery
Understanding the structure-activity relationship is critical in efficient and effective drug discovery and development. However, a conceptual understanding alone is not enough to make the most use of this relationship.
Effective scientific data analysis and visualization software can help improve performance and productivity. SAR-focused digital tools allow researchers to identify correlations and construct molecular models to help predict biological activity.
This use case requires access and manipulation of data, incorporating an array of different tools. With Dotmatics, scientists have access to high-performance data visualization and analytical tools that support scientific decision-making. For example, researchers can conduct cheminformatics analyses, even using SAR.
Related
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
Our 11 Most-Read Blogs of 2023: AI, Biologics, ELNs, and More
Dotmatics' top blogs of 2023 highlight key scientific advancements including the convergence of small molecule and biologic drug development, the integration and comparison of LIMS and ELN systems for enhanced lab data management, and strategies to minimize human errors in biologics research through automation and calibration.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.
3 Drug Discovery Trends We’re Watching in 2025
The ebook highlights three key drug discovery trends for 2025: the impactful use of AI in predictive modeling and data integration, the rise of multimodal discovery platforms like Geneious Luma that unify research across therapeutic modalities, and the Lab-in-a-Loop approach that leverages AI-driven integration of R&D and clinical data to accelerate and optimize drug development.
How AI is Transforming Drug Discovery
Dotmatics executives Kalim Saliba and Steve Tharp explain in an NBC News Boston feature how AI is revolutionizing drug discovery by enabling researchers to navigate complex data more efficiently, significantly reducing development time and costs, and accelerating the creation of safer, personalized medicines.